Trial Profile
A Multicenter, International, Randomised, Double-blind, Placebo Controlled Study to Demonstrate the Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs ABT 011 (Primary)
- Indications Allergic rhinoconjunctivitis; Grass pollen hypersensitivity
- Focus Registrational; Therapeutic Use
- Sponsors ASIT biotech; BioTech Tools; DMS Imaging
- 04 Mar 2019 Results demonstrating immunologic mechanisms of gpASIT+TM immuno-therapy in a subset of patients from Belgium in this trial published in the Journal of Allergy and Clinical Immunology.
- 12 Mar 2018 According to an ASIT biotech media release, company published new article presenting the results from this study in the scientific journal ALLERGY, the official journal of the European Academy of Allergy and Clinical Immunology (EAACI).
- 05 Mar 2018 Results evaluating quality of life during hey fever season presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology